SOUTH SAN FRANCISCO, Calif., Apr 14, 2010 (BUSINESS WIRE) --Exelixis, Inc. (Nasdaq:EXEL) announced today that data from clinical trials of the company's investigational compounds XL184, XL147, XL765, XL228 and XL139 will be presented at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 4-8 in Chicago, Illinois. Lead compound XL184 will be the subject of four separate presentations, including an oral presentation of clinical data from the ongoing phase 2 trial in patients with progressive glioblastoma. PI3K pathway inhibitors XL147 and XL765 will be the subject of six separate presentations. Exelixis is co-developing XL184 and XL139 with Bristol-Myers Squibb Company. Sanofi-aventis has a worldwide, exclusive license to XL147 and XL765.

Presentations Featuring XL184 (MET, VEGF, RET)

• Oral presentation: Data from a phase 2 study of XL184 in patients with progressive glioblastoma will be presented on Saturday, June 5, 2010 from 5:00-5:15PM local time (Abstract #2006).
• Oral presentation: Long-term results in a cohort of medullary thyroid cancer patients in a phase 1 study of XL184 will be presented in a clinical science symposium on Monday, June 7 at 10:45-11:00AM (Abstract #5502).
• Poster discussion: Data from a phase 1b/2 study of XL184 with and without erlotinib in patients with non-small cell lung cancer will be presented on Sunday, June 6, 2010 during the 2:00-6:00PM session with a discussion from 5:00-5:15PM (Abstract #3017).
• Trials in Progress section: Data from an adaptive randomized discontinuation trial of XL184 in patients with advanced solid tumors will be presented on Monday, June 7, 2010 during the 8:00AM - 4:00PM session (Abstract #TPS188).

Presentations Featuring XL147 (PI3K) and XL765 (PI3K, MTOR)

• Oral presentation: Data from a phase 1 dose-escalation study of XL147 administered orally to patients with advanced malignancies will be presented in a clinical science symposium on Monday, June 7, 2010 from 8:30-8:45AM local time (Abstract #3004).
• Poster discussion: Data from a phase 1 safety and pharmacokinetic study of XL765 in combination with erlotinib in patients with advanced solid tumors will be presented on Sunday, June 6, 2010 during the 2:00-6:00PM session with a discussion from 5:00-5:15PM (Abstract #3015).
• Poster discussion: Data from a phase 1 dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of XL765 administered orally to patients with advanced malignancies will be presented on Sunday, June 6, 2010 during the 2:00-6:00PM session with a discussion from 5:45-6:00PM (Abstract #3030).
• Poster presentation: Data from a phase 1 safety and pharmacokinetic study of XL147 in combination with erlotinib in patients with advanced solid tumors will be presented on Monday, June 7, 2010 during the 8:00AM - noon session (Abstract #3070).
• Poster presentation: Data from a phase 1 safety and pharmacokinetic study of XL147 in combination with paclitaxel and carboplatin in patients with advanced solid tumors will be presented on Monday, June 7, 2010 during the 8:00AM - noon session (Abstract #3078).
• Poster presentation: Data from a phase 1 safety and pharmacokinetic study of XL765 in combination with temozolomide in patients with newly diagnosed malignant glioma will be presented on Monday, June 7, 2010 during the 8:00AM - noon session (Abstract #3085).

Additional Presentations Featuring Exelixis Compounds

• XL139 oral presentation: Data from a first-in-human, phase 1 study of XL139 in subjects with advanced or metastatic solid tumors will be presented in a clinical science symposium on Sunday, June 6, 2010 from 10:15-10:30AM local time. Submitted for presentation by Bristol-Myers Squibb.
• XL228 poster presentation: Data from a phase 1 study of XL228, a multitargeted protein kinase inhibitor, in patients with solid tumors or multiple myeloma will be presented on Monday, June 7 from 8:00 AM - noon session (Abstract #3105).

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, sanofi-aventis, GlaxoSmithKline, Genentech (a wholly owned member of the Roche Group), Boehringer Ingelheim, Pfizer Inc., and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

SOURCE: Exelixis, Inc.

Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President
Corporate Communications
& Investor Relations
cbutler@exelixis.com